News | November 22, 2013

GE Healthcare Receives Approval for Its Own Manufacturing of Optison

Optison Remains an Important Diagnostic Option for Patients With Suboptimal Echocardiograms

November 22, 2013 – GE Healthcare announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to manufacture Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP) in-house. Optison is a contrast agent that may improve the visualization of the left ventricular border ? an area of the heart that is critical to see in order to assess and diagnose certain heart diseases. As a result of the FDA’s action, GE Healthcare will provide a supply of Optison to the U.S. and European markets from its manufacturing facility in Oslo, Norway, becoming the only contrast media manufacturer to supply its own stock to the United States.

“Adding our own manufacturing site for Optison has multiple benefits for physicians and patients, including an ability to increase capacity to meet market demands and help to ensure consistent supply to the contrast media market,” said Jan Makela, GM, Core Imaging, GE Healthcare Life Sciences.

“In part because of interrupted supply, ultrasound contrast media usage has yet to reach its full potential, so we are quite pleased that GE Healthcare has made this commitment and investment to independently manufacture Optison within its own facility,” said Benjamin F. Byrd, III, MD, FASE, President, American Society of Echocardiography. “Optison remains an important diagnostic option for patients who present with suboptimal echocardiograms. The Society believes that use of contrast in echocardiography studies can enhance the image and thus reduce the need for additional testing, helping to lower healthcare costs and provide better patient care.”

Optison is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricle and to improve delineation of the left ventricular endocardial borders. Optison is not for use in patients with known or suspected right-to-left, bi-directional, or transient right-to-left cardiac shunts or hypersensitivity to perflutren, blood, blood products, or albumin. It should not be administered by intra-arterial injection. As for all ultrasound contrast agents, Optison has a boxed warning indicating that serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration. Most serious reactions occur within 30 minutes of administration. Healthcare professionals should assess all patients for the presence of any condition that precludes Optison administration and always have resuscitation equipment and trained personnel readily available.

For more information: www3.gehealthcare.com/en

Related Content

Siemens Healthineers Launches Acuson Sequoia Ultrasound
Technology | Ultrasound Imaging | July 12, 2018
July 12, 2018 — Siemens Healthineers recently announced the launch of its new ultrasound system, the Acuson Sequoia.
EchoNous Vein Receives FDA Approval to Improve First-Time Peripheral IV Catheter Insertion
Technology | Ultrasound Imaging | July 12, 2018
EchoNous has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the EchoNous Vein, an ultrasound-...
Hologic Announces Availability of Viera Portable Breast Ultrasound System
Technology | Ultrasound Women's Health | July 11, 2018
Hologic’s new Viera portable breast ultrasound system is now available for purchase in the United States and Europe....
Guerbet, IBM Watson Health Partner on Artificial Intelligence for Liver Imaging
News | Clinical Decision Support | July 10, 2018
Guerbet announced it has signed an exclusive joint development agreement with IBM Watson Health to develop an...
Healcerion Receives FDA Approval for Sonon 300L Handheld Ultrasound Device
Technology | Ultrasound Imaging | July 09, 2018
South Korea-based Healcerion launched the Sonon 300L wireless handheld ultrasound device to the U.S. market following U...
Neural Analytics Inc. Receives CE Mark for Robotic Ultrasound System
Technology | Ultrasound Imaging | July 03, 2018
Medical robotics company Neural Analytics Inc. announced that it received CE Mark for its NeuralBot System, a robotic...
Konica Minolta Launches Sonimage MX1 Portable Ultrasound System
Technology | Ultrasound Imaging | June 28, 2018
Konica Minolta Healthcare Americas Inc. introduced the Sonimage MX1 portable ultrasound system, optimized for...
EchoMD AutoEF Software Improves Variability in Ejection Fraction Estimation
News | Cardiovascular Ultrasound | June 27, 2018
A recent study conducted with the Minneapolis Heart Institute found that Bay Labs’ EchoMD AutoEF deep learning software...
Technology | Focused Ultrasound Therapy | June 19, 2018
EDAP TMS SA has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Focal One device for...
Epsilon Imaging Demonstrates Strain Imaging Integration for Echo Programs at ASE 2018
News | Cardiovascular Ultrasound | June 19, 2018
Clinical practice, along with guidelines and research, have shown that speckle tracking strain imaging can improve...
Overlay Init